Neutra Life Sciences Expands Clinical Research Footprint with Key Partnerships

Neutra Corp's subsidiary, Neutra Life Sciences, is making significant strides in the clinical research industry with its Site Management Organization (SMO), securing joint venture partnerships across podiatry, radiation oncology, and dermatology specialties. This expansion includes collaborations with Epic Foot & Ankle Centers, Aspire Hospital Cancer Centers, and Radiant Dermatology & Aesthetics Clinic, positioning Neutra Life Sciences for substantial growth in 2025 and 2026. The company's strategic focus on diversifying its clinical research capabilities aims to meet the growing demand for innovative treatments and patient care solutions. Neutra Corp's President and CEO, Sydney Jim, emphasizes the importance of these partnerships in fostering innovation and expanding service offerings. Additionally, Neutra Corp has decided to divest its hemp-based cannabis subsidiary, VIVIS Corporation, to concentrate on its life sciences and clinical research endeavors, highlighting its commitment to regulatory stability and long-term market potential.

For more details on Neutra Life Sciences' expansion and how to participate in clinical trials, visit Neutra Corp's website or contact them directly. This strategic growth underscores Neutra Corp's dedication to advancing healthcare through research and innovation, offering a broader spectrum of therapeutic solutions to a wider patient population.